Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder caused by a toxic CTG repeat expansion in the 3′UTR of the *DMPK* gene.^[@R1][@R2][@R3]^ In adults with DM1, symptoms are characterized by progressive distal muscle weakness, myotonia, early onset cataracts, cardiac and gastrointestinal problems, and dysfunction in the CNS.^[@R4],[@R5]^ The multiorgan involvement is often more pronounced and with earlier onset in individuals with symptom onset in childhood. The age of onset of DM1 is variable, and intergenerational repeat expansion (known as anticipation) may result in symptom onset during childhood. When symptom onset occurs at birth, this is known as congenital onset myotonic dystrophy (CDM). Symptom onset after the newborn period and up to 18 years of age is typically referred to as childhood-onset myotonic dystrophy (ChDM). However, alternate definitions designate further cut points depending on age of onset.^[@R6],[@R7]^ Although the exact global prevalence is unknown, children with CDM likely represent 10%--30% of the overall DM1 population.^[@R4],[@R8]^

These disorders cause significant morbidity and mortality. Children with CDM often require intensive intervention at birth because of hypotonia, respiratory failure, and feeding difficulties.^[@R4],[@R9]^ For children with CDM ventilated longer than 3 months, there is a 30% mortality in the first year of life.^[@R10]^ Both children with CDM and ChDM may have symptoms associated with attention deficit hyperactivity disorder or autism spectrum disorder (sometimes referred to as social communication disorder) during childhood.^[@R11],[@R12]^ They also have significant motor delays^[@R13]^ and may have intractable irritable bowel symptoms, including incontinence. Previous research suggests that 88% of individuals with congenital or childhood-onset myotonic dystrophy are unemployed over the age of 18 years.^[@R14]^

The multisystemic nature, morbidity, and mortality associated with congenital and childhood-onset myotonic dystrophy necessitate the development of care recommendations to standardize care. These consensus-based recommendations will also set the foundation for innovative clinical initiatives where gaps exist and also further research to improve aspects of management. These care recommendations may also better prepare the pediatric DM1 community for future clinical trials because variation in clinical care may have significant effects on the outcome of children participating in geographically dispersed clinical research sites.

Methods {#s1}
=======

Participant recruitment {#s1-1}
-----------------------

The Myotonic Dystrophy Foundation recruited clinicians from the United States, Canada, and Europe who have experience in the treatment of children with DM1 to develop consensus-based recommendations.

Consensus approach {#s1-2}
------------------

As previously described, the Myotonic Dystrophy Foundation developed a two-phase consensus building methodology using components of the single text procedure and nominal group technique.^[@R15]^ This approach was chosen given both the sparsity of literature surrounding many of the clinical aspects and the extensive experience of the clinicians in this area.

Three of the authors (N.E.J., C.C., and E.Z.) created the initial draft document, drawing from the existing literature and clinical practice that served as an initial text for the recommendation developments.

After creation of the single text, stakeholders were engaged to refine the recommendations through a consensus-based approach. The experts were initially assigned to specific areas of recommendations, where they refined the recommendations. A facilitator (LH) then lead a series of meetings to review, revise, and finalize the recommendations with the entire author panel.

These efforts led to the final consensus-based care recommendations along with a quick reference guide. The care recommendations are divided into 2 main sections, the General Care Considerations and Systems-based Approach to Management. Because there are differences between childhood-onset and congenital-onset DM1, recommendations specific to CDM are separated throughout the document. The Quick Reference Guide is provided as an appendix, and the full document is available online (appendix e-1, [links.lww.com/CPJ/A89](http://links.lww.com/CPJ/A89)). Both feature flowcharts and other infographics for ease of use.

Results {#s2}
=======

See full recommendations at [Neurology.org/cp](http://cp.neurology.org/lookup/doi/10.1212/CPJ.0000000000000646).

General care considerations {#s3}
===========================

Diagnosis and classification {#s3-1}
----------------------------

The diagnosis of DM1 should be suspected in any child with a family history of DM1 and/or presenting with one or more of the following features:◦ Eyelid ptosis and/or oral motor weakness◦ Distal weakness, primarily of the finger and wrist flexors, without contractures, or weakness of the neck flexors◦ Myotonia or "stiffness" of muscles◦ Autistic features or social communication difficulties◦ Attention deficit disorder, anxiety, and other behavioral problems◦ Developmental delay and/or Intellectual disability◦ Learning disabilities (e.g., dyslexia, dyscalculia)◦ Excessive daytime sleepiness (EDS)◦ Gastrointestinal issues: constipation or diarrhea◦ Scoliosis◦ Arrhythmia◦ Prolonged recovery or respiratory arrest after anesthesia◦ Neonatal features of hypotonia, weakness, club foot, respiratory distress, or feeding problemsThe classification of congenital and childhood-onset DM1 is provided in table 1 in Quick Reference Guide. Note that diagnosis may be made retrospectively after reviewing symptom onset. Fetal tissue with long CTG repeats should not be called CDM because this diagnosis is reserved for newborns. In these cases, we would suggest use of fetal DM1 as more appropriate.Genetic counseling is recommended for patients exhibiting clinical signs indicative of DM1, or have at-risk family members, to enable them to make an informed decision about whether to proceed to genetic testing. Individuals with 37--49 CTG repeats are deemed very unlikely to develop detectable DM1 symptoms. However, such "premutations" can expand into the disease range in subsequent generations, particularly when transmitted by women. Individuals thus identified should be offered genetic counseling (see Genetic counseling) to discuss their risk for transmitting DM1.

Genetic counseling {#s3-2}
------------------

Referral to genetic counseling (see [nsgc.org](http://nsgc.org)) is recommended for all patients with congenital and childhood-onset DM1 and their parents and to assess the parents for the diagnosis of DM1.Genetic counseling in affected families should convey information about:◦ The inheritance pattern of disease (autosomal dominant inheritance)◦ The wide variability in the scope and severity of DM1 symptoms, even within the same family◦ The possibility of changes in symptom scope and severity over time◦ The likelihood that the mutation will expand and the disease will become more severe as it is passed from generation to generation (anticipation)◦ Particular attention to the possibility of a minimally affected mother giving birth to a severely affected child◦ Options for family planningDo not use CTG repeat numbers, if available, for genetic advice or prognostication; these need to be discussed with a genetic counselor. Specifically, repeat size may be an indicator of severity, but it does not provide any information about the prognosis.

### Focus on CDM {#s3-2-1}

Once a family has had a child with CDM, there is an increased risk that the next affected child with DM1 is likely to have congenital form as well.

Neonatal care {#s3-3}
-------------

A high**-**risk obstetrician should provide prenatal obstetric care for mothers known or suspected to carry a child with DM1.Pediatric or neonatal specialist should be present at delivery if a mother is known to have DM1 or if the child is known or suspected to have DM1.

### Focus on CDM {#s3-3-1}

Children with CDM will often need management in a neonatal intensive care unit with the capability to deal with breathing and feeding support. This team requires a range of neonatal and consulting specialists who can manage the genetic, respiratory, gastrointestinal, orthopedic, neuromuscular, neurosurgical, and cardiac issues. See figure 1 in Quick Reference Guide for neonatal care.

End of life counseling and management {#s3-4}
-------------------------------------

Recommend the introduction of palliative care at the time of diagnosis and at regular intervals thereafter. When a formal pediatric palliative care team is available, they should be consulted.Recognize and address caregiver burden, whether the caregiver has DM1, offering respite care or equivalent measures to patient to improve family support. Address normal grief on the part of the patient and family and offer counseling as appropriate.Establish an emergency health care plan and advance directives with the family.

### Focus on CDM {#s3-4-1}

Introduce the concept that the natural history of the disease includes progressive improvement of strength for the first decade of life; however, the complications of CDM can be critical and have a high risk of mortality, particularly in the first year of life.Advise families or caregivers that invasive and noninvasive ventilation (NIV) and nutrition through gastrostomy tube are acceptable parts of care for patients with CDM.

Surgery and anesthesia {#s3-5}
----------------------

Inform all caregivers that anyone administering an anesthetic should be aware of the DM1 diagnosis.When possible combine procedures under a single sedation.Arrange for a preanesthetic visit for all children planning to have deep sedation for a diagnostic test, procedure, or surgery. If possible, include a pulmonologist with expertise in neuromuscular diseases during this visit.Even if the patient has mild DM1, monitoring for a longer period of time than is typical following anesthesia or surgery will allow for identifying serious adverse events in the hospital setting.Providers are encouraged to review the Myotonic Dystrophy Foundation *Practical Suggestions for the Anesthetic Management of a Myotonic Dystrophy Patient* ([myotonic.org/sites/default/files/MDF_LongForm_AnesGuidelines_01C.pdf](http://www.myotonic.org/sites/default/files/MDF_LongForm_AnesGuidelines_01C.pdf)) for anesthesia risks and recommendations before any surgeries or procedures requiring anesthesia and the *Anesthesia Quick Reference Guide* ([myotonic.org/sites/default/files/MDF Anesthesia Guidelines FNL 2016 2 2. pdf](http://myotonic.org/sites/default/files/MDF%20Anesthesia%20Guidelines%20FNL%202016%202%202.%20pdf)). These documents should be reviewed before treatment decisions.

### Focus on CDM {#s3-5-1}

It is worth noting that children with CDM are at a higher risk of anesthetic complications, given the underlying respiratory involvement, as opposed to those with childhood-onset myotonic dystrophy.

Systems-based approach to management {#s4}
====================================

Respiratory {#s4-1}
-----------

Signs of respiratory problems in children with myotonic dystrophy include ineffective cough, recurrent pulmonary infections, orthopnea, dyspnea, poor sleep, morning headaches, apnea, fatigue, and snoring.See figure 2 in Quick Reference Guide for a flowchart of testing and treatment options in congenital and childhood-onset myotonic dystrophy.

Focus on CDM {#s4-2}
------------

For CDM children who remain on longer term trach ventilation, there is often improvement in respiratory strength over time, and consideration to decannulate a tracheostomy should be made after careful consideration with the multidisciplinary team including neurology; respirology; ear, nose, and throat; and the family. Consideration of airway control, respiratory infection frequency, ability to tolerate a facial or nasal mask for NIV and compliance and cooperation with maintenance pulmonary therapy such as cough assist, breathe staking, etc. Testing for hypoventilation in sleep should be done before decannulation.

Cardiovascular {#s4-3}
--------------

Inform families of the risks of arrhythmias and cardiac dysfunction and the importance of prompt medical attention if symptoms are observed (i.e., palpitations, presyncope, syncope, dyspnea, chest pain, unexplained fatigue).◦ A 12-lead ECG should be performed at DM1 diagnosis, and if normal and the patient remains asymptomatic, ECG should be performed annually and warrants more investigation if the patient is symptomatic.◦ If the ECG is normal and clinical suspicion is high, a 24-hour Holter monitor may be considered as a second-line investigation.◦ Because specific medications such as mexiletine and psychostimulants are antiarrhythmic, an ECG before use, again within 3 months of starting therapy, and then at serial intervals is recommended.◦ Consider in-hospital cardiac monitoring to detect arrhythmias if admitted for longer duration than typical after surgical procedures or if admitted due to severe illness or infectionFor young DM1 patients, serial exercise stress testing and signal-averaged ECGs may be considered.Evaluate and treat using American Heart Association (AHA) *Management of Cardiac Involvement Associated With Neuromuscular Diseases A Scientific Statement From the American Heart Association* 2017 [circ.ahajournals.org/content/136/13/e200.long](http://circ.ahajournals.org/content/136/13/e200.long) and ACC (\[American College of Cardiology\]/AHA)/ESC (European Society of Cardiology) *Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death* (see [ncbi.nlm.nih.gov/pubmed/16949478)-](http://www.ncbi.nlm.nih.gov/pubmed/16949478)-) section on pediatric issues 13.4.

Skeletal muscle weakness, orthopedic complications, and rehabilitation {#s4-4}
----------------------------------------------------------------------

Children should be evaluated early and often for physical, occupational, and speech therapy needs with specific attention to:◦ Feeding concerns and dysphagia◦ Gross motor delay◦ Gross and fine motor weakness◦ Dysarthria and potential augmentative and alternative communication needs◦ Language acquisition delaysThe spine should be assessed for scoliosis and, if necessary, consider bracing or referral to orthopedic surgeon.Children should be encouraged to participate in speech therapy targeting speech, language, and communication from a very early age.

### Focus on CDM {#s4-4-1}

Newborns with CDM often having difficulty feeding and alternative nutrition should be considered. After about a year of actively working with a speech therapist or occupational therapist, most children can generally start on oral feeding.Children with CDM experience progressive improvement in their proximal strength until adolescence, at a minimum. Therefore, children should be encouraged to participate in physical activities.Prevention of joint contractures are key to management and should be closely monitored with early initiation of stretching. Treatment of talipes equinovarus and other joint contractures should include initial stretching regimen and appropriate ankle bracing (for talipes equinovarus). Serial casting may be considered.

Skeletal muscle myotonia {#s4-5}
------------------------

Delayed relaxation after grip or percussion, difficulty related to activities of daily life, progressive speech impairment, or profound irritable bowel symptoms are signs often related to myotonia.Mexiletine (Mexitil) is an option for myotonia, if it is demonstrated and is distressing to the patient. Mexiletine may not be approved for use in every country. In these cases, other sodium channel antagonists may be considered.◦ Because mexiletine is an antiarrhythmic, an ECG before use, again within 3 months of starting therapy, and then at serial intervals is recommended.◦ Instruct the patient to avoid dyspepsia and transient "dizzy feelings" associated with mexiletine treatment by taking it with food to extend absorption and lower peak level in blood.

Ocular and hearing management {#s4-6}
-----------------------------

Baseline audiometry should be performed, especially at school age.Ophthalmologic assessment should be performed at diagnosis and at least yearly to evaluate for hyperopia, stigmatism, strabismus, and visual acuity to prevent evolution of visual impairment.Eyelid ptosis; if ptosis becomes severe and interferes with vision, intervention such as eyelid "crutches" that can be inserted into glasses may be warranted. Try crutches as a remedy for ptosis before eyelid surgery is considered because of anesthesia risks. Ophthalmic lubricants for dry eye may be considered.

Gastrointestinal and genitourinary management {#s4-7}
---------------------------------------------

Presence of gastrointestinal symptoms such as abdominal pain, constipation, fecal incontinence, or diarrhea may be a frequent problem. The symptoms may mimic irritable bowel syndrome (IBS).^[@R15]^ Fiber supplementation (more than 8 g daily) is the first-line treatment.Gentle laxatives (see below) for constipation. Oils should be avoided as they will lead to diarrhea. If a patient does not respond to the first- or second-line recommendations below, a referral to a gastrointestinal specialist for anal manometry should be considered:◦ First-line therapy recommendations: polyethylene glycol (Miralax), senna (Ex-Lax, Senokot), docusate (Colace), or lactulose (Cholac)◦ Second-line therapy recommendations: bisacodyl (Dulcolax, Correctol), lubiprostone (Amitiza), or linaclotide (Linzess)◦ Metoclopramide (Reglan) may be used to reduce the symptoms of gastroparesis, pseudo-obstruction, and gastric reflux. Providers should be aware of the risk of acute dystonic reactions with this medication. Long-term use is not recommended because this drug can cause tardive dyskinesia.◦ Cholestyramine and loperamide are other options in the presence of mainly diarrhea and anticholinergic drug such as hyoscyamine sulfate in the presence of IBS. Because anticholinergic drugs may be antiarrhythmic, see Cardiac section on management.◦ Mexiletine may be considered for refractory diarrhea or constipation because the drug may be antiarrhythmic, see Cardiac section on management.If bacterial overgrowth is found on breath testing, treating with antibiotics may reduce diarrhea.

### Focus on CDM {#s4-7-1}

As mentioned in the neonatal care section, children with CDM may require a temporary feeding tube. If dysphagia persists, consider enteral nutrition. Refer to speech therapy. Children should be periodically re-assessed for improving dysphagia.Children with CDM often benefit from dysphagia therapy. With aggressive dysphagia therapy, children with CDM often are able to feed orally within the first year of life.

Neurodevelopmental management {#s4-8}
-----------------------------

### Recommendations {#s4-8-1}

Neuropsychological testing should be performed in every child with DM1 to delineate cognitive strengths and weaknesses. This may include the following:◦ Psychometric assessment of global intellectual ability and adaptive functioning◦ Assessment of executive functions◦ Assessment of social cognition◦Assessment of visuomotor integration and visuospatial ability◦ Assessment of receptive and expressive language abilities◦ Assessment of EDS◦ Assessment of learning disabilities (specific tests for dyscalculia, dyslexia, and dyspraxia)The assessments should be performed in the congenital form in preschool age and should be repeated, depending on the level of functioning, 2--3 times before adulthood. In childhood DM1, neuropsychological testing is recommended at diagnosis and repeated in preschool or school age and college period.Patients with psychiatric or behavioral issues should be referred to a mental health care professional for assessment of Autism Spectrum Disorders, Attention Deficit disorders with or without Hyperactivity, alexiythmia, and other behavioral problems.Psychostimulants may be beneficial if attention deficits are associated with an impairing level of fatigue or EDS (see excessive daytime sleepiness). As psychostimulants may be proarrhythmic, see Cardiac section on stimulant management:◦ Serotonin-enhancing antidepressants if excessive anxiety or other treatable psychiatric symptoms are present◦ Specific cognitive remediation programs to enhance social emotional abilities (visual contact, joint attention, emotional regulation) or executive functions efficiency (inhibitory control, attention, working memory, and cognitive flexibility) using dedicated software (e.g., Cogmed®)Language remediation and reading therapy should be considered because of the presence of cognitive deficits, even in children with normal intelligence. Attention deficit, fatigability, and visual--spatial construction dysfunction can result in specific learning disorders with impairment in reading and spelling as well as in mathematics.

Psychosocial management {#s4-9}
-----------------------

Healthcare professionals have a responsibility to coordinate specialist care and support services for children with DM1. There is a need to be alert to the psychological and social dysfunctions and monitor home and educational circumstances. Liaison between agencies is essential to ensure a consistent approach between health, education, and social care agencies.Children with DM1 should have access to appropriate psychological and therapy services at an early age to ensure they are fulfilling their maximum potential and learning coping strategies for later life. The modification of activities including social engagement strategies would provide a foundation for each child to grow in confidence and esteem.Family care and support is essential throughout childhood with support and social care assistance where required. Schools should be provided with specialist information about the care and management of a child with DM1. A social work consult or a referral to nursing case management can also be beneficial for patients. A holistic approach is critical because the affected parent may also need additional assistance.Families should have access to disability benefits, adequate housing and adaptations during the progression of the condition.

Excessive daytime sleepiness {#s4-10}
----------------------------

Family members and educators should be educated about the EDS that comes with DM1.Children should be screened for signs of EDS, including prolonged naps or falling asleep in school.Possible sleep apnea should be evaluated with overnight oximetry or polysomnogram.Positive-pressure ventilation can be considered if a DM1 patient\'s sleepiness is thought to be related to nocturnal or daytime hypoventilation or sleep apnea. Patients should be referred to pulmonologists who have experience in neuromuscular diseases for consideration of assisted ventilation.Stimulant therapy with a psychostimulant such as modafinil (Provigil), methylphenidate, or other stimulant can be considered if central hypersomnia is suspected. Often difficulty staying awake in school is a triggering factor. Special care should be taken in children with previously detected cardiac arrhythmia (See Cardiac section on stimulant management).

Endocrine and metabolism {#s4-11}
------------------------

DM1 male patients should undergo a detailed physical examination in search of gonadal atrophy or cryptorchidism.Patients should have a HbA1c and thyroid-stimulating hormone and Free T4 level measured at baseline and every 3 years, or if there is a clinical suspicion.Adolescent patients should be screened as adult patients:◦ Gonadal insufficiency and complications of the reproductive system: Inquiring about amenorrhea or dysmenorrhea for the female patients, and erectile dysfunction for male patients◦ Fasting blood lipids, plasma glucose, liver enzymes, bilirubin levels, and gamma-glutamyl transpeptidase should be measured at baseline.

Conclusions {#s5}
===========

The recommendations for care of congenital and childhood-onset myotonic dystrophy have been created by consensus of clinicians experienced in their care management. Given the absence of rigorous studies in many of these areas, these guidelines were created by consensus. They are designed to standardize the care of children with a multisystemic disorder that leads to significant morbidity and mortality.
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